Assessment of Your Notes: Parkinson's Disease & Anti-Parkinson's Drugs

What Your Notes Cover (Summary of Transcription)

• Pharmacology of Anti-Parkinson's drugs (AP)
• Extra Pyramidal Syndrome (EPS) - involving ↑ Acetylcholine / ↓ Dopamine (pointing to Parkinson's)
• Progressive disease - neurological disorder that damages the dopamine-producing brain cells - leads to primary motor symptoms
• Resting tremor, muscle stiffness (rigidity), bradykinesia, slowness of movement

• Depression or excitement, cognitive impairment, dementia
• Causes: exact causes linked to death of vital neurons in the brain that produce dopamine - the chemical messenger responsible for smooth control of movements
• Risk factors: genetic, environmental
• Medications' side effects; neurodegenerative disease; Ex - haloperidol causing psychotic drug; toxin or stroke; basal ganglia
• All structural brain regions associated with parkinsonism
• Symptoms: typically starting in the hands, making simple tasks like buttoning the shirt or hurrying slow - bradykinesia, non-motor signs - before motor signs, experiences loss of sense of smell, sleep disorder, mood changes

• a) Dopamine precursor - Ex: Aldopa, Levo-dopa
• b) Peripheral decarboxylase inhibitors - Ex: Carbidopa, Benserazide
• c) Dopamine facilitators - Ex: Amantadine
• d) Dopaminergic agonist - Ex: Ropinirole, Pramipexole
• e) MAO-B inhibitors - Ex: Selegiline, Rasagiline
• f) COMT inhibitors - Ex: Entacapone, Tolcapone

• a) Central anticholinergics - Ex: Procyclidine, Biperiden
• b) Antihistamine - Ex: Diphenhydramine, Promethazine

• Levodopa acts as levodopa (L-dopa)
• Levodopa improves all the manifestations of parkinsonism, initially there is a subtle tremor - also helps with hypertension (likely "hypotension")
• Parkinsonism is ineffective in drug-induced parkinsonism - peripherally formed dopamine can act on receptors

• Nausea, vomiting
• Postural/orthostatic hypotension
• Cardiac - arrhythmias (listed as cardiac changes)
• Exacerbation of angina
• Tachycardia by acting on β-adrenergic receptors
• Peripherally formed dopamine can act on the CTZ (Chemoreceptor Trigger Zone) - causing nausea, vomiting, allergic reactions
• Inhibits prolactin secretion

Verdict: Are These Notes Adequate?

✅ What Is Correct and Complete

⚠️ Corrections and Improvements Needed

The pathological hallmark of PD is Lewy bodies (intracellular inclusions of aggregated α-synuclein) in the substantia nigra pars compacta. A loss of 70-80% of DA-containing neurons accompanies symptomatic PD.

• Goodman & Gilman's, p. 434

• You wrote "Aldopa" as the dopamine precursor - this should be Levodopa (L-DOPA). "Aldopa" is not a standard drug name. The example under category (a) is levodopa itself, so writing "Ex: Aldopa, Levodopa" is redundant/incorrect.

L-Dopa (Levodopa) - Mechanism of Action:

• DA itself cannot cross the blood-brain barrier (BBB), so levodopa (its metabolic precursor) is used instead
• Levodopa crosses the BBB via a membrane transporter for aromatic amino acids
• After crossing the BBB, levodopa is decarboxylated to dopamine (by AADC enzyme) primarily within the presynaptic terminals of dopaminergic neurons in the striatum
• The dopamine produced restores dopaminergic tone in the nigrostriatal pathway, reducing the motor symptoms of PD
• When given alone, most levodopa is decarboxylated peripherally (in gut mucosa/liver) - less than 1% reaches the CNS
• Therefore, it is always combined with a peripheral AADC inhibitor (carbidopa/benserazide), which prevents peripheral breakdown, increases CNS availability, and reduces peripheral side effects (nausea, vomiting, hypotension)
• After release, dopamine is either taken back up into terminals or metabolized by MAO and COMT

📝 What to Add for Full Marks

1. Definition: PD = progressive neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra pars compacta, leading to dopamine deficiency in the striatum. Pathological hallmark = Lewy bodies.
2. Classification Table (you have this - just fix "Aldopa"):

1. L-Dopa Pharmacological Action - Write the mechanism clearly as described above (BBB crossing, decarboxylation in striatum, why combined with carbidopa).
2. Add to Adverse Effects: Dyskinesias (long-term), "wearing off" / "on-off" phenomenon, psychiatric effects (hallucinations, psychosis with long-term use).

Final Score Estimate

• ✅ Accurate at every step
• ✅ Concise and logical - examiners love flowcharts
• ✅ Covers the core mechanism clearly

Here is the complete, exam-ready version with a few additions:

Levodopa (oral)
    ↓ absorbed from small intestine via amino acid transport system
    ↓ enters circulation (peak plasma level in 0.5–2 hours)
    ↓ crosses BBB via aromatic amino acid transporter
      (Dopamine itself CANNOT cross BBB — that's why L-Dopa is used)
    ↓ converted to DOPAMINE by DOPA decarboxylase (AADC) in CNS
      (mainly in presynaptic terminals of striatal dopaminergic neurons)
    ↓ replenishes dopamine in striatum (caudate + putamen)
    ↓ restores dopamine-acetylcholine balance
    → IMPROVEMENT of motor symptoms
      (reduces tremor, rigidity, bradykinesia)

Why These Additions Matter

One More Point to Add After the Flowchart

Note: In clinical practice, levodopa is always combined with carbidopa (a peripheral AADC inhibitor) to prevent peripheral conversion of levodopa to dopamine outside the CNS. This reduces side effects (nausea, vomiting, hypotension) and increases the amount of levodopa reaching the brain.

Parkinson's Disease & Anti-Parkinson's Drugs

1. Definition of Parkinson's Disease

• It is a group of movement disorders caused by degeneration in the basal ganglia, responsible for smooth control of voluntary muscles and coordination.
• No treatment is said to manage the symptoms completely.

• ↑ Acetylcholine
• ↓ Dopamine

📝 ADD: The pathological hallmark is Lewy bodies (intracellular inclusions of aggregated α-synuclein) in the substantia nigra. A loss of 70-80% of dopamine-containing neurons accompanies symptomatic PD.

2. Causes of PD

• Medication side effects - e.g., haloperidol (antipsychotic drug)
• Neurodegenerative disease
• Huntington's disease
• Toxin or stroke
• Basal ganglia - all structural brain regions

• Genetic
• Environmental

3. Symptoms of PD

• Resting tremor
• Muscle stiffness (rigidity)
• Slowness of movement (bradykinesia)
• 4 cardinal symptoms - typically starting in the hands, making simple tasks like buttoning the shirt or hurrying slow (bradykinesia)

• Loss of sense of smell
• Sleep disorder
• Mood changes
• Depression or excitement
• Cognitive impairment
• Dementia

4. Classification of Anti-Parkinson's Drugs

I. Drugs Affecting the Dopaminergic System

• Ex: Levodopa (L-Dopa)

📝 CORRECTION: Remove "Aldopa" - it is not a standard drug name. Levodopa is the correct drug name.

• Ex: Carbidopa, Benserazide

• Ex: Amantadine

• Ex: Ropinirole, Pramipexole

📝 ADD: Bromocriptine is another example

• Ex: Selegiline, Rasagiline

• Ex: Entacapone, Tolcapone

II. Drugs Affecting Brain Cholinergic System

• Ex: Procyclidine, Biperiden

📝 ADD: Trihexyphenidyl (most commonly used)

• Ex: Diphenhydramine, Promethazine

5. Pharmacological Action of Levodopa

Mechanism of Action (Flowchart):

Levodopa (oral)
    ↓ absorbed from small intestine via amino acid transport system
    ↓ enters circulation (peak plasma level in 0.5–2 hours)
    ↓ crosses BBB via aromatic amino acid transporter
      (Dopamine itself CANNOT cross BBB — that's why L-Dopa is used)
    ↓ converted to DOPAMINE by DOPA decarboxylase (AADC) in CNS
      (mainly in presynaptic terminals of striatal dopaminergic neurons)
    ↓ replenishes dopamine in striatum (caudate + putamen)
    ↓ restores dopamine-acetylcholine balance
    → IMPROVEMENT of motor symptoms
      (reduces tremor, rigidity, bradykinesia)

📝 ADD THIS IMPORTANT POINT: In clinical practice, levodopa is always combined with carbidopa (a peripheral AADC inhibitor that does NOT cross BBB). This:

• Prevents peripheral conversion of levodopa to dopamine outside the CNS
• Increases the amount of levodopa reaching the brain
• Reduces peripheral side effects (nausea, vomiting, hypotension)

6. Adverse Effects of Levodopa

• Nausea
• Vomiting
• Postural hypotension
• Cardiac arrhythmias
• Exacerbation of angina
• Tachycardia (by acting on β-adrenergic receptors)

• Peripherally formed dopamine acts on the CTZ (Chemoreceptor Trigger Zone) → causes nausea, vomiting
• Acts as immune modulator → causing allergic reactions
• Inhibits prolactin secretion

📝 ADD - Central (Long-term) Effects:

• Dyskinesias - involuntary movements (choreoathetosis) - occur in ~50% patients after 5 years
• "On-Off" phenomenon - periods when drug works ("on") vs. poor response ("off") - wearing off effect
• Hallucinations, psychosis (psychiatric effects)

Quick Summary of What to Add vs. What You Already Have:

Epilepsy, Anti-Epileptic Drugs & Pharmacological Action of Phenytoin

(5 Marks Answer)

1. Definition of Epilepsy

📝 THIS IS MISSING FROM YOUR SCREENSHOT - ADD THIS FIRST

• A seizure is defined as uncontrolled excessive electrical discharges in the brain that may produce a sudden change in brain function causing physical convulsion, minor physical signs, thought disturbances, or a combination of symptoms.
• Epilepsy is diagnosed when a person has 2 or more unprovoked seizures separated by more than 24 hours.
• Status epilepticus = continuous seizure activity for more than 5 minutes - a medical emergency.

2. Anti-Epileptic Drugs (Anticonvulsants)

• Anticonvulsants are a diverse group of pharmacological agents used in the treatment of epileptic seizures.
• They are also used in bipolar disorder, borderline personality disorder (as mood stabilizers), and neuropathic pain.

3. Classification of Anti-Epileptic Drugs

4. Phenytoin

• Phenytoin belongs to the Hydantoin class of anticonvulsants.
• Used to control focal seizures, generalized tonic-clonic seizures, and status epilepticus.
• Works by decreasing abnormal electrical activity in the brain.

5. Pharmacological Action of Phenytoin

📝 YOUR SCREENSHOT IS TOO BRIEF HERE - THIS SECTION NEEDS THE MOST ADDITIONS FOR 5 MARKS

Mechanism of Action (Flowchart):

Abnormal high-frequency neuronal firing occurs in epilepsy
    ↓
Voltage-gated sodium (Na⁺) channels open repeatedly
    ↓
Phenytoin binds selectively to Na⁺ channels
in the INACTIVATED state
    ↓
Slows the rate of recovery of Na⁺ channels
(channel remains inactivated/blocked longer)
    ↓
Prevents rapid repetitive firing of action potentials
    ↓
Inhibits positive feedback loop of neuronal propagation
    ↓
Stabilizes the neuronal membrane
    → SUPPRESSION of seizure activity

Key Points about the Mechanism:

• Phenytoin is a use-dependent (frequency-dependent) blocker - it blocks channels MORE during rapid firing (epileptic activity) and has LESS effect on normal slow neuronal firing
• This is why it selectively suppresses seizures without significantly sedating the patient at therapeutic doses
• It acts on III-S6 and IV-S6 segments of the sodium channel protein (binding site)
• It has NO effect on GABA or chloride channels (unlike barbiturates/benzodiazepines)

6. Adverse Effects of Phenytoin

📝 ALSO MISSING FROM YOUR SCREENSHOT - ADD THESE

• Nystagmus (first sign of toxicity)
• Ataxia (most common dose-related effect requiring dose adjustment)
• Diplopia (double vision)
• Sedation (at high doses)
• The elderly are highly susceptible to CNS effects

• Gingival hyperplasia - gums grow over teeth (characteristic side effect of phenytoin)
• Hirsutism (abnormal hair growth)
• Peripheral neuropathy
• Osteoporosis
• Megaloblastic anaemia (folate deficiency)

• Phenytoin shows nonlinear (saturable) pharmacokinetics - a small increase in dose can cause a large increase in plasma concentration → toxicity risk
• Narrow therapeutic index drug

Quick Summary - What to Add to Your Screenshot

Definition of Epilepsy

• A seizure is diagnosed when a person has 2 or more unprovoked seizures separated by more than 24 hours.
• It may cause physical convulsions, loss of consciousness, or sensory disturbances.

Quick Tips for 2-Mark Questions: